The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1078
May 15, 2000
View Complete Issue         Table of Contents 2019 
Dofetilide for Atrial Fibrillation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dofetilide for Atrial Fibrillation
May 15, 2000 (Issue: 1078)
Dofetilide (Tikosyn - Pfizer), a new methanesulfonamide antiarrhythmic drug, has recently been marketed for oral treatment of atrial fibrillation and flutter.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Dofetilide for Atrial Fibrillation
Article code: 1078a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.